We are developing innovative drugs to target challenging protein-protein interactions in cancer, leveraging our proprietary phenotypic drug discovery platform. Having successfully completed hit validation for our first program, we are now seeking seed investors to advance to the lead identification stage.
Recent news
- RIANA at BioEurope 2025 in Vienna
From November 3–5, the RIANA team was delighted to participate in BioEurope 2025, hosted this year in our beautiful home city of Vienna. It was an inspiring few days filled with engaging conversations, valuable new connections, and the opportunity to reconnect with many familiar faces from the biotech community. A special highlight was Anna’s pitch … - RIANA Therapeutics Wins First Prize at Prague.bio 2025
On September 25, 2025, RIANA Therapeutics took part in the Prague.bio Conference 2025, one of Central and Eastern Europe’s leading events for the biotechnology and life sciences community. The conference brought together founders, investors, scientists, and innovation leaders from across the region — all sharing a common goal: to strengthen and connect the CEE biotech …Continue reading “RIANA Therapeutics Wins First Prize at Prague.bio 2025”
- RIANA at Krebsforschungslauf 2025
Together we go further! On Saturday morning, October 4, the RIANA team joined the Krebsforschungslauf (Cancer Research Run) at the Medical University of Vienna. The weather was perfect, the atmosphere uplifting, and the event beautifully organized by the MedUni Vienna team. We truly enjoyed running together for such a meaningful cause – with every single … - Meet us at these upcoming conferences 2025We look forward to networking with venture capital, business angels and industry leaders, discussing how RIANA’s STAT5 inhibitor program is paving the way for new treatments in oncology. If you’ll be there, we’d love to connect!
- RIANA among 20 most innovative start-ups in Austria
Vienna, Nov 9 2024 What an honor! We are proud to share that RIANA Therapeutics has been named one of Austria’s Top 20 Most Innovative Start-ups by Trend. magazine! We’re truly honored by this recognition. A big thank you to the jury for their support and belief in our vision. Thank you to everyone who’s …Continue reading “RIANA among 20 most innovative start-ups in Austria”
- Meet us at the RESI London Conference
Dec 4, 2024 | London, UK Meet our CBO, Christine Ruckenbauer, in person on December 4 or online afterwards, December 4-5. The RESI (Redefining Early Stage Investments) event in London is the perfect platform for early-stage biotech startups like RIANA Therapeutics to connect with potential investors, explore funding opportunities, and showcase our innovative approach to … - Biotech – Langer Atem, hoher Impact
In a recent article for the Brutkasten magazine RIANA Therapeutics CEO Anna Orlova, Christopher Trummer (Celeris Therapeutics), and Peter Llewellyn-Davies (President Biotech-Austria) discuss the challenges and opportunities facing the biotech industry. “It is always difficult to explain to people who are not familiar with the life science industry what our challenges are and why we … - RIANA at the Vienna Business Run 2024
September 4 2024 | Vienna, Austria RIANA team had an incredible time running! The energy, teamwork, and camaraderie made it unforgettable. We were proud to send two teams of three this year, and the best part? We improved our results from 2023! It was a perfect day to step away from the lab, have fun, … - Meet us at BIO-Europe 2024
November 4-11, 2024 | Stockholm, Sweden We are delighted to announce that RIANAtx will be attending the BIO-EUROPE partnering conference, from November 4th to November 11th in the beauftiful city of Stockholm. We look forward to presenting our recent data and connecting with leading business executives and early-stage investors in the life sciences and biotech community to foster new and … - Scientific Advisory BoardVienna, June 2024. We are pleased to announce the formation of our Scientific Advisory Board (SAB), which includes leading experts in the field of cancer research and small molecule development. This milestone marks a significant step forward in our mission to demonstrate how our platform screening approach for protein-protein interaction inhibitors and our pipeline molecules …
RIANA Therapeutics 